fbpx

Brain Cancer

Cerebral Glioblastoma

Female, 63 years

Patient Internal 8161276

ICD-10 code

C71.8 Malignant Neoplasm of Overlapping Sites of Brain

Diagnosis (Incl. Metastases/Stage) and Year

February 2019
Malignant glioma G2 according to WHO, IDH1/2 unmutated, TERT promoter mutation C250T.
Progression in March 2022. The second craniotomy – glioblastoma G4 according to WHO, IDH not mutated.

Previous Treatment

Surgery (Craniotomy) 2 times, Radiation Therapy, Chemotherapy (Temozolomide).

Prognosis and Survival Expectation

The prognosis remains poor, with a median survival of ~14 months from diagnosis

Treatment Provided

Allogenic DCV (8 doses) and CIK (1 dose) over a period of 32 months.

Patient Survival/Condition and Year
Date of Review: 25/01/2024

The patient has survived 44 months since the diagnosis. It can be concluded that the addition of Immunotherapy, alongside Surgery, Radiation therapy and Chemotherapy, has benefited the patient in disease stabilisation and has extended patient survival by an estimate of 30 months.

Disclaimer

We encourage you to learn more about your condition and treatment options to make informed decisions about your healthcare. However, please keep in mind that not all information available online or in other sources is accurate or relevant to your specific situation. It’s important to rely on credible, evidence-based sources such as official medical websites, peer-reviewed publications, or information provided by professional healthcare organizations. Always discuss any information you find with your healthcare provider before making decisions, as they can help clarify details, address concerns, and ensure the information is appropriate for your unique needs.

Ok